Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPRAB study (MITO 36)
2024-518847-40-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and trabectedin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Policlinico Gemelli. Primary endpoint: Tumor response per RECIST 1.1. Planned start Nov 2024; status: authorised.
02
Drugs
pegylated liposomal doxorubicintrabectedin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-518847-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518847-40-00.